Benjamin Y. Jin

Benjamin Y. Jin

Auto-generated profile, based on publicly available information

Benjamin Y. Jin

Genitourinary Malignancy Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RNRosa Nguyen
Rosa Nguyen
EDEkaterina Doubrovina
Ekaterina Doubrovina
CMCharlotte M. Mousset
Charlotte M. Mousset
BJBenjamin Y. Jin
Benjamin Y. Jin
ROReona Okada
Reona Okada
CHChristian S. Hinrichs
Christian S. Hinrichs
Purpose: Chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies are effective in a subset of patients with solid tumors, but new approaches are needed to universally improve patient outcomes. Here, we developed a technology to leverage the cooperative effects of IL15 and IL21, two common cytokine-receptor gamma chain family members with distinct, pleiotropic effects on T cells and other lymphocytes, to enhance the efficacy of adoptive T cells. Experimental Design: We designed vectors that induce the constitutive expression of either membrane-tethered IL15, IL21, or IL15/IL21. We used clinically relevant preclinical models of transgenic CARs and TCRs against pediatric and adult solid tumors to determine the effect of the membrane-tethered cytokines on engineered T cells for human administration. Results: We found that self-delivery of these cytokines by CAR or TCR T cells prevents functional exhaustion by repeated stimulation and limits the emergence of dysfunctional natural killer (NK)-like T cells. Across different preclinical murine solid tumor models, we observed enhanced regression with each individual cytokine but the greatest antitumor efficacy when T cells were armored with both. Conclusions: The coexpression of membrane-tethered IL15 and IL21 represents a technology to enhance the resilience and function of engineered T cells against solid tumors and could be applicable to multiple therapy platforms and diseases. See related commentary by Ruffin et al., p. 1431

15 April 2024
Verified
Other
Open access
PDF file
RNRosa Nguyen
Rosa Nguyen
EDEkaterina Doubrovina
Ekaterina Doubrovina
CMCharlotte M. Mousset
Charlotte M. Mousset
BJBenjamin Y. Jin
Benjamin Y. Jin
ROReona Okada
Reona Okada
CHChristian S. Hinrichs
Christian S. Hinrichs
Growth kinetics of transduced T-cells following single-transduction with cytokine vector and IL-2 removal.

15 April 2024
Verified
Other
Open access
PDF file
RNRosa Nguyen
Rosa Nguyen
EDEkaterina Doubrovina
Ekaterina Doubrovina
CMCharlotte M. Mousset
Charlotte M. Mousset
BJBenjamin Y. Jin
Benjamin Y. Jin
ROReona Okada
Reona Okada
CHChristian S. Hinrichs
Christian S. Hinrichs
Growth kinetics and copy number analysis of transgene.

15 April 2024
Verified
Other
Open access
PDF file
RNRosa Nguyen
Rosa Nguyen
EDEkaterina Doubrovina
Ekaterina Doubrovina
CMCharlotte M. Mousset
Charlotte M. Mousset
BJBenjamin Y. Jin
Benjamin Y. Jin
ROReona Okada
Reona Okada
CHChristian S. Hinrichs
Christian S. Hinrichs
Body weights from mice with orthotopic neuroblastoma that were treated with adoptive T-cells.

15 April 2024
Verified
Other
Open access
PDF file
RNRosa Nguyen
Rosa Nguyen
EDEkaterina Doubrovina
Ekaterina Doubrovina
CMCharlotte M. Mousset
Charlotte M. Mousset
BJBenjamin Y. Jin
Benjamin Y. Jin
ROReona Okada
Reona Okada
CHChristian S. Hinrichs
Christian S. Hinrichs
Replicate rechallenge experiment in vitro.

15 April 2024
Verified
Other
Open access
PDF file
RNRosa Nguyen
Rosa Nguyen
EDEkaterina Doubrovina
Ekaterina Doubrovina
CMCharlotte M. Mousset
Charlotte M. Mousset
BJBenjamin Y. Jin
Benjamin Y. Jin
ROReona Okada
Reona Okada
CHChristian S. Hinrichs
Christian S. Hinrichs
Replicate in vivo adoptive TCR T-cell studies.